DocWire News Editors

DocwireNews

A meta-analysis, conducted by Wu Ye and collaborators from the Department of Hematology at the West China Hospital, Sichuan University in Sichuan Province, China, evaluated monoclonal antibodies (MAbs) with three different targets when used in combination with bortezomib or immunomodulators and dexamethasone/prednisone in the treatment of patients with multiple myeloma (MM).Published in BMC Cancer, their report relayed that patients treated with MAbs targeting CD38 had longer progression-free survival (PFS) and better treatment response than patients in the SLAMF7 or PD-1/PD-L1 groups. The SLAMF7-directed treatment, though not as effective as the CD38 MAbs, was associated with the lowest incidence of grade III or higher neutropenia. MAbs targeting PD-1/PD-L1 performed the worst, and the researchers recommend against their use in patients with MM.The study included 5,367 patients from 11 randomized controlled trials that used at least one of the indicated MABs. They reported hazard ratios (HRs) for overall survival (OS) and PFS, grade III or higher adverse events, as well as relative risk (RR) for overall response rate, complete response (CR) or better, very good partial response (VGPR) or better, VGPR, partial response, and stable disease among the three groups.The study authors calculated the HRs for PFS between the following MAb target groups:<ul>
<li>CD38 versus SLAMF7: 0.662 (95% CI, 0.543&ndash;0.806)</li>
<li>CD38 versus PD-1/PD-L1: 0.317 (95% CI, 0.221&ndash;0.454)</li>
<li>SLAMF7 versus PD-1/PD-L1: 0.479 (95% CI, 0.328&ndash;0.699)</li>
</ul>Additionally, the HR for OS of the CD38 group versus the SLAMF7 group was 0.812 (95% CI, 0.584&ndash;1.127), the RR for CR or better of CD38 versus SLAMF7 was 2.253 (95% CI, 1.284&ndash;3.955), and the RR for neutropenia of CD38 vs SLAMF7 was 1.818 (95% CI, 1.41&ndash;2.344).The analysis was limited in that the number of studies testing SLAMF7 and PD-1/PD-L1-specific MABs was too small to draw conclusions from, and pooled RRs for treatment response relative to controls between the included studies were heterogenous. Additionally, the authors stated that original, individual patient data would have been more valuable than the abstracted data used for analysis.&nbsp;According to the authors, this is the first analysis of different MABs when combined with other agents in the treatment of patients with MM. In general, the MAbs targeting CD38 in combination with bortezomib/immunomodulators plus dexamethasone/prednisone showed significant therapeutic value&mdash;though MAbs targeting PD-1/PD-L1 performed the worst. MAbs targeting SLAMF7 were not as effective as MAbs targeting CD38, however, they resulted in a lower incidence of adverse events in patients.&nbsp;Given the different effects observed between the various MABs and treatment combinations, the authors suggested that their report &ldquo;could provide a resource for clinicians when selecting an antibody to combine with other drugs for the treatment of MM.&rdquo;

Roger Rodby, MD

Joel M. Topf, MD, FACP

Seldin Award Winner Advocates Online Education

NKF Spring Clinical Meetings 2025

Hatem Soliman, MD

The Future of Dendritic Cell Vaccines in HER2+ Breast Cancer: Toward De-Escalation of Chemotherapy

HER2 Breast Cancer

Jordana Jampel

Mechanism of Positive Association Between Parkinson’s Disease and Melanoma Revealed in New Research

Melanoma

Latest News

Comparing Different Monoclonal Antibodies Within a Treatment Strategy for Patients with Multiple Myeloma

Oncology

A meta-analysis, conducted by Wu Ye and collaborators from the Department of Hematology at the West China Hospital, Sichuan University in Sichuan Province, China, evaluated ...

Comparing Different Monoclonal Antibodies Within a Treatment Strategy for Patients with Multiple

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe